Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$49.86 USD
+1.93 (4.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $49.83 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APLS 49.86 +1.93(4.03%)
Will APLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
Other News for APLS
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Apellis announces pegcetacoplan MAA review has been reset to Day 180
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Impact of Izervay’s Growth on Apellis Pharmaceuticals: Maintaining a Hold Rating Amidst Rising Competition